Experimental CAR-T therapy shows early promise in Tough-to-Treat myeloma
NCT ID NCT04322292
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new CAR-T cell therapy called C-CAR088 in 9 patients with multiple myeloma that had returned or stopped responding to treatment. The therapy uses a patient's own immune cells, modified to target a protein called BCMA on myeloma cells. The main goals were to check safety and see if the treatment could shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
C-CAR088 (a type of CAR-T cell therapy targeting BCMA)
What this could lead to
If successful, this could point toward a new treatment option for patients with multiple myeloma that has stopped responding to standard therapies.
What could go wrong
This is a very early phase 1 trial with only 9 participants, so results may not apply broadly. CAR-T therapies can cause serious side effects like cytokine release syndrome.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
InstituteHBDH
Tianjin, 300000, China